• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Residual Cardiovascular Risk Determined through Posthoc Analysis of the REAL-CAD Trial.

作者信息

Endo Yasuhiro, Sasaki Kei, Ikewaki Katsunori

机构信息

Division of Anti-aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College.

Division of Environmental Medicine, National Defense Medical College Research Institute.

出版信息

J Atheroscler Thromb. 2024 Jan 1;31(1):21-22. doi: 10.5551/jat.ED245. Epub 2023 Oct 17.

DOI:10.5551/jat.ED245
PMID:37853635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10776336/
Abstract
摘要

相似文献

1
Residual Cardiovascular Risk Determined through Posthoc Analysis of the REAL-CAD Trial.通过REAL-CAD试验事后分析确定的残余心血管风险。
J Atheroscler Thromb. 2024 Jan 1;31(1):21-22. doi: 10.5551/jat.ED245. Epub 2023 Oct 17.
2
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.心血管-肾脏生物标志物可溶性尿激酶型纤溶酶原激活物受体与冠心病患者心血管死亡和心肌梗死相关，与肌钙蛋白、C 反应蛋白和肾功能无关。
J Am Heart Assoc. 2020 Apr 21;9(8):e015452. doi: 10.1161/JAHA.119.015452. Epub 2020 Apr 17.
3
Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients.低舒张压可能不是经血管重建的冠心病患者心血管死亡的独立危险因素。
J Hypertens. 2011 Oct;29(10):1889-96. doi: 10.1097/HJH.0b013e32834a5a67.
4
Genetic Liability to Depression and Risk of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes.抑郁症遗传易感性与冠心病、心肌梗死及其他心血管结局的风险。
J Am Heart Assoc. 2021 Jan 5;10(1):e017986. doi: 10.1161/JAHA.120.017986. Epub 2020 Dec 29.
5
Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease.类风湿关节炎对合并和不合并冠状动脉疾病患者主要心血管事件的影响。
Ann Rheum Dis. 2020 Sep;79(9):1182-1188. doi: 10.1136/annrheumdis-2020-217154. Epub 2020 May 29.
6
Cardiovascular risk factors and major recurrent coronary events: A genetic liability study in patients with coronary artery disease in the UK Biobank.心血管风险因素与主要复发性冠状动脉事件：英国生物库中冠状动脉疾病患者的遗传易感性研究。
Atherosclerosis. 2023 Jul;376:19-25. doi: 10.1016/j.atherosclerosis.2023.05.011. Epub 2023 May 24.
7
[New opportunities of antithrombotic therapy in patients with type 2 diabetes mellitus and stable coronary heart disease for reducing the cardiovascular risk and cardiovascular complications: THEMIS, THEMIS-PCI trials].[2型糖尿病合并稳定型冠心病患者抗栓治疗降低心血管风险及心血管并发症的新机遇：THEMIS、THEMIS-PCI试验]
Ter Arkh. 2022 Nov 22;94(10):1204-1210. doi: 10.26442/00403660.2022.10.201911.
8
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis.钙补充剂联合或不联合维生素 D 与心血管事件风险：妇女健康倡议有限访问数据集的重新分析和荟萃分析。
BMJ. 2011 Apr 19;342:d2040. doi: 10.1136/bmj.d2040.
9
Effect of Colchicine in Reducing Inflammatory Biomarkers and Cardiovascular Risk in Coronary Artery Disease: A Meta-analysis of Clinical Trials.秋水仙碱对降低冠心病炎症生物标志物和心血管风险的影响：临床试验的荟萃分析。
Am J Ther. 2023 May 1;30(3):e197-e208. doi: 10.1097/MJT.0000000000001409.
10
Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation.代谢综合征改变女性血管造影显示的冠状动脉疾病相关心血管风险：来自女性缺血综合征评估的报告。
Circulation. 2004 Feb 17;109(6):714-21. doi: 10.1161/01.CIR.0000115517.26897.A7.

引用本文的文献

1
Association between the High-density Lipoprotein Cholesterol Efflux Capacity and the Long-term Prognosis in Patients with Coronary Artery Disease: A Meta-analysis.高密度脂蛋白胆固醇流出能力与冠心病患者长期预后的关联：一项荟萃分析
J Atheroscler Thromb. 2025 Apr 1;32(4):491-501. doi: 10.5551/jat.65171. Epub 2024 Oct 24.

本文引用的文献

1
Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study.他汀类药物治疗的稳定性冠心病患者非脂残余风险因素与心血管事件的关系：REAL-CAD 研究观察。
J Atheroscler Thromb. 2024 Jan 1;31(1):61-80. doi: 10.5551/jat.64304. Epub 2023 Aug 11.
2
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.炎症驱动慢性肾脏病的残余风险：一项CANTOS子研究
Eur Heart J. 2022 Dec 7;43(46):4832-4844. doi: 10.1093/eurheartj/ehac444.
3
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.依洛尤单抗对心肌梗死后他汀类药物治疗患者的冠状动脉斑块表型和负担的影响。
JACC Cardiovasc Imaging. 2022 Jul;15(7):1308-1321. doi: 10.1016/j.jcmg.2022.03.002. Epub 2022 Mar 16.
4
Relationship Between Non-fasting Triglycerides and Cardiovascular Disease Mortality in a 20-year Follow-up Study of a Japanese General Population: NIPPON DATA90.日本一般人群 20 年随访研究中非空腹甘油三酯与心血管疾病死亡率的关系：NIPPON DATA90。
J Epidemiol. 2022 Jul 5;32(7):303-313. doi: 10.2188/jea.JE20200399. Epub 2021 Jun 22.
5
Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.富含甘油三酯的脂蛋白残粒、糖尿病与心血管疾病。
Diabetes. 2020 Apr;69(4):508-516. doi: 10.2337/dbi19-0007.
6
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
7
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
8
Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study.小而密的低密度脂蛋白胆固醇浓度可预测冠心病风险：动脉粥样硬化风险社区（ARIC）研究。
Arterioscler Thromb Vasc Biol. 2014 May;34(5):1069-77. doi: 10.1161/ATVBAHA.114.303284. Epub 2014 Feb 20.
9
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).脂蛋白(a)浓度、瑞舒伐他汀治疗与残余血管风险：来自 JUPITER 试验（他汀类药物预防的理由：评估瑞舒伐他汀的干预试验）的分析。
Circulation. 2014 Feb 11;129(6):635-42. doi: 10.1161/CIRCULATIONAHA.113.004406. Epub 2013 Nov 17.
10
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.强效他汀类药物治疗后首次心血管事件残余风险的高密度脂蛋白胆固醇：来自 JUPITER 试验的分析。
Lancet. 2010 Jul 31;376(9738):333-9. doi: 10.1016/S0140-6736(10)60713-1. Epub 2010 Jul 23.